Orosomucoid 1 promotes colorectal cancer progression and liver metastasis by affecting PI3K/AKT pathway and inducing macrophage M2 polarization.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 08 2023
28 08 2023
Historique:
received:
15
04
2023
accepted:
09
08
2023
medline:
31
8
2023
pubmed:
29
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
Approximately 25-30% of those affected by colorectal cancer (CRC), the most prevalent gastrointestinal malignancy, develop metastases. The survival rate of patients with liver metastasis of CRC (CRLM) remains low owing to its unpredictability and a lack of biomarkers that can be applied to distinguish groups at higher risk for CRLM among patients with CRC. Therefore, our study aimed to find biomarkers that can predict the risk of CRLM. Screening of the Gene Expression Omnibus database, supported by an analysis of clinically obtained tissue and serum data using qPCR and ELISA, in an attempt to identify relevant biomarkers, enabled us to determine that orosomucoid 1 (ORM1) was differentially expressed in liver metastases and primary tumors of patients with CRC. Functionally, overexpression of ORM1 promoted the epithelial-mesenchymal transition and the proliferative, migratory, and invasive activities of MC38 cells and activated the PI3K/AKT signaling pathway. Moreover, MC38 cells overexpressing ORM1 enhanced the tumor immune microenvironment by promoting macrophage M2 polarization and elevating interleukin-10 (IL-10) expression. In vivo experiments further confirmed in vitro results, indicating that liver metastases elevated by ORM1 were partially attenuated by the depletion of macrophages or IL-10. Considered together, ORM1 promotes CRC progression and liver metastasis by regulating tumor cell growth and inducing macrophage M2 polarization, which mediates tumor immune tolerance, and thus acts as a potential predictive marker and therapeutic target in CRLM.
Identifiants
pubmed: 37640741
doi: 10.1038/s41598-023-40404-1
pii: 10.1038/s41598-023-40404-1
pmc: PMC10462626
doi:
Substances chimiques
Orosomucoid
0
Interleukin-10
130068-27-8
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14092Informations de copyright
© 2023. Springer Nature Limited.
Références
J Cancer Res Clin Oncol. 2019 Mar;145(3):725-736
pubmed: 30542791
J Surg Oncol. 2010 Dec 15;102(8):898-908
pubmed: 21165991
Comb Chem High Throughput Screen. 2018;21(10):755-759
pubmed: 30663564
Cancer Metastasis Rev. 2016 Dec;35(4):515-524
pubmed: 27896521
J Exp Clin Cancer Res. 2018 Dec 5;37(1):304
pubmed: 30518405
Prz Gastroenterol. 2019;14(2):89-103
pubmed: 31616522
J Cell Physiol. 2017 Dec;232(12):3261-3272
pubmed: 28079253
Nat Neurosci. 2016 Jan;19(1):20-7
pubmed: 26713745
Cancer Treat Rev. 2004 Apr;30(2):193-204
pubmed: 15023437
Gut. 2019 Dec;68(12):2179-2185
pubmed: 31488504
Vet Res. 2004 Mar-Apr;35(2):163-87
pubmed: 15099494
J Immunol. 2002 Jul 1;169(1):384-92
pubmed: 12077268
Chin Med J (Engl). 2021 Jul 7;134(16):1941-1951
pubmed: 34238851
Neurol Res. 2019 May;41(5):399-412
pubmed: 30707086
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Liver Cancer. 2016 Nov;6(1):66-71
pubmed: 27995090
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592
pubmed: 36300620
J Microbiol Biotechnol. 2020 Sep 28;30(9):1297-1304
pubmed: 32627751
Bioengineered. 2021 Dec;12(1):8822-8832
pubmed: 34654351
World J Gastroenterol. 2020 Feb 28;26(8):804-817
pubmed: 32148378
Mol Cancer. 2021 Dec 18;20(1):167
pubmed: 34922544
Dev Cell. 2019 May 6;49(3):361-374
pubmed: 31063755
Cytokine. 2015 May;73(1):8-15
pubmed: 25689617
Methods Mol Biol. 2016;1418:93-110
pubmed: 27008011
Apoptosis. 2004 Nov;9(6):667-76
pubmed: 15505410
Am J Physiol Gastrointest Liver Physiol. 2018 Jan 1;314(1):G22-G31
pubmed: 29025731
Front Oncol. 2021 Aug 19;11:714866
pubmed: 34490113
Int J Oncol. 2016 Oct;49(4):1651-65
pubmed: 27511453
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732
pubmed: 31455888
Ann Surg. 2008 Jan;247(1):125-35
pubmed: 18156932
Sci Rep. 2016 Mar 29;6:23695
pubmed: 27021626
Int J Oncol. 2021 Jan;58(1):70-82
pubmed: 33367926
Vox Sang. 1993;64(1):47-55
pubmed: 8447119
FEBS J. 2020 Feb;287(4):783-799
pubmed: 31482685
Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2):G305-G312
pubmed: 31736338
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Aging (Albany NY). 2020 May 8;12(9):7985-8000
pubmed: 32385195
Adv Mater. 2020 Oct;32(40):e2002054
pubmed: 32856350
PLoS One. 2012;7(8):e41387
pubmed: 22916107
Semin Cancer Biol. 2019 Dec;59:147-160
pubmed: 31128298
Protein Sci. 2019 Nov;28(11):1947-1951
pubmed: 31441146
J Physiol Biochem. 2015 Jun;71(2):329-40
pubmed: 25711902
Cell Commun Signal. 2020 Mar 30;18(1):51
pubmed: 32228612
Cancer Res. 2021 Sep 1;81(17):4545-4559
pubmed: 34210751
Bosn J Basic Med Sci. 2022 Oct 23;22(6):949-958
pubmed: 35765957
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Life Sci. 2020 Dec 1;262:118513
pubmed: 33011222
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645